8-K: Cencora Expands Retina Business with EyeSouth Acquisition

Cencora announced a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion, expanding its Retina Consultants of America network.

Summary

• Cencora, Inc. entered into a definitive agreement on March 21, 2026, to acquire EyeSouth Partners' retina business for $1.1 billion.
• Upon completion of the transaction, the affiliated retina physicians of EyeSouth Partners will join Cencora's Retina Consultants of America (RCA).
• The acquisition is expected to be slightly accretive, net of financing costs, to Cencora's adjusted diluted EPS in the first twelve months following transaction closing.
• The transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory approvals.
• Cencora reaffirmed its fiscal 2026 financial guidance, which does not currently contemplate the transaction closing in its fiscal 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a strategically positive move, expanding Cencora's specialized healthcare services and expected to be accretive to earnings, despite the transaction closing outside the current fiscal year.

Positives

• Strategic expansion of the Retina Consultants of America (RCA) network, enhancing Cencora's specialized healthcare services.
• Expected to be slightly accretive to adjusted diluted EPS in the first twelve months following transaction closing, net of financing costs.
• Strengthens Cencora's commitment to supporting community physicians and providing world-class retina care.
• EyeSouth Partners physicians will gain expanded access to innovative treatments through RCA's clinical trial and research offerings.

Risks

• The parties' ability to meet expectations regarding the timing of the proposed transaction.
• The parties' ability to consummate the proposed transaction.
• Regulatory approvals required for the proposed transaction not being obtained on the terms expected, on the anticipated schedule, or at all.
• Inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and financial measures.
• Cencora's or EyeSouth Partners' failure to achieve expected or targeted future financial and operating performance and results.
• The possibility that Cencora may be unable to achieve expected benefits, synergies, and operating efficiencies in connection with the proposed transaction within the expected time frames or at all.
• Business disruption being greater than expected following the proposed transaction.
• The recruiting and retention of key physicians and employees being more difficult following the proposed transaction.
• The effect of any changes in customer and supplier relationships and customer purchasing patterns.
• The impacts of competition.
• Changes in the economic and financial conditions of the business of Cencora or EyeSouth Partners.
• Cencora's de-leveraging plans and the ability to maintain its investment grade rating.
• Uncertainties and matters beyond the control of management and other factors described in Cencora's SEC filings.

Future Outlook

Cencora expects the acquisition to be slightly accretive to its adjusted diluted EPS, net of financing costs, in the first twelve months post-closing. The company reaffirmed its fiscal 2026 financial guidance, which does not currently include the transaction closing within that fiscal year.

Management Comments

• "By joining RCA, these physicians will become part of an organization with capabilities designed to provide world-class retina care and be supported by Cencora's longstanding commitment to community physicians." Robert P. Mauch, President and Chief Executive Officer of Cencora.
• "We look forward to collaborating with the well-trained and respected EyeSouth Partners physicians as we work together to advance sight-saving treatment for patients." David Brown, M.D., Chief Medical Officer, RCA.
• "Our physicians will drive expanded access to innovative treatments through RCA's clinical trial and research offerings while continuing to work with EyeSouth Partners to support patient access across the ophthalmology landscape." Atul Sharma, M.D., EyeSouth Partners Board Member.

Industry Context

StockSavvy.ai notes this acquisition strengthens Cencora's position in the specialized ophthalmology market, particularly within retina care, by expanding its Retina Consultants of America (RCA) network. This move aligns with a broader trend in healthcare of consolidating specialized physician practices under larger management services organizations to leverage scale, improve operational efficiencies, and enhance access to advanced treatments and clinical research.

Stakeholder Impact

• Shareholders: Expected positive impact due to anticipated EPS accretion and strategic growth in a specialized healthcare segment.
• Employees (EyeSouth Partners physicians): Will join RCA, benefiting from its resources, clinical trial, and research offerings, potentially enhancing career opportunities.
• Patients: Expected to benefit from expanded access to world-class retina care and innovative treatments through the larger RCA network.
• Competitors: Cencora's expanded footprint in retina care could intensify competition in the ophthalmology management services organization (MSO) market.

Next Steps

• Satisfaction of customary closing conditions, including receipt of required regulatory approvals.
• Integration of EyeSouth Partners' retina physicians into Retina Consultants of America (RCA).

Key Dates

Recommendation

The acquisition of EyeSouth Partners' retina business for $1.1 billion is a strategic expansion for Cencora, strengthening its specialized healthcare services through Retina Consultants of America. The expected slight accretion to adjusted diluted EPS in the first twelve months post-closing, coupled with the expansion into a growing healthcare segment, suggests a positive long-term outlook. While the transaction is not expected to close in fiscal 2026, the strategic rationale and anticipated financial benefits make this a favorable development for the company's growth trajectory.

Keywords

Cencora, COR, EyeSouth Partners, acquisition, retina business, Retina Consultants of America, RCA, ophthalmology, healthcare, pharmaceutical solutions, MSO, EPS accretion